Wednesday, 20 May 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 20 May 2026
News

Drug pulled after less than 3 years

Posted 20 May 2026 PM

AstraZeneca has decided to pull Andexxa from the Australian market from today, rather than pursue full registration for the anticoagulant reversal agent.

Andexxa was provisionally registered on the ARTG on 3 July 2023 for adult patients treated with a direct factor (FXa) inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

To see the whole article, please login

Popular

World's Most Innovative Pharma is...
Inside Aussie Med Affairs salaries
Aussie GM steps up to regional role
Drugs battle for US$2.7B market
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home